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Abstract 
For pharmacist-provided Medication Therapy Management (MTM) services to operate effectively and efficiently, pharmacists must 
understand the process of MTM delivery, assess the barriers and challenges in creating a sustainable MTM program, and realize the 
willingness and readiness of their colleagues to deliver such services. In order to assess feasibility of such services among high-risk 
neighborhoods in New York City (NYC), a focus group design was used to qualitatively assess pharmacists’ perceptions of MTM. 
Findings showed that reimbursement and allocation of resources were the most discussed challenges/barriers to the provision of 
pharmacist-provided MTM services. Overall, pharmacists were willing, but not yet ready, to provide MTM services on a large scale. 
Lack of understanding of MTM structure/process, reimbursement challenges, and the need for collaboration between providers were 
key components to pharmacists’ willingness to provide services. Additional training opportunities were deemed necessary for them to 
feel confident to conduct clinical services. Although pharmacists discussed several issues regarding MTM, they were still interested in 
participating and seeing how MTM would impact their community practice settings. Understanding these perceptions of pharmacists 
on MTM allowed us to better understand and assess ways for continuous quality improvement of services that will enhance patient 
care. 
 
 
Introduction 
In 2010, the U.S. health care system was transformed with 
the passage of the Patient Protection and Affordable Care Act 
(PPACA). The underlying force behind the health care reform 
legislation was improving quality of care while decreasing 
health care costs. With this new legislation, pharmacists may 
have an opportunity to be part of the effort to help improve 
patient outcomes and reduce costs by utilizing their expertise 
in medication management. In particular, emphasis was 
placed on health care delivery with team-based care acting as 
a driving force for quality improvement, cost containment,  
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and outcomes assessment.
1 An explicit team-based model of 
care is the patient-centered medical home (PCMH). PCMH is a 
delivery system wherein patients obtain care from a variety 
of providers based on their individualized needs, with an 
emphasis on the primary care team focusing on care 
coordination and quality improvement.
2   Studies have 
demonstrated that pharmacists participating in team-based 
care in acute care or outpatient clinic settings have made 
positive contributions to patient care quality and safe 
medication use.
3 The PCMH movement provides an 
opportunity for pharmacists to affect the delivery of primary 
care through the utilization of medication therapy 
management (MTM). 
 
Additionally, in light of recent changes within the New York 
State Medicaid Redesign Team
4 to reduce costs and improve 
care, the New York State Department of Health introduced 
the concept of Health Homes.
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Health Homes also strive to accomplish the goals of 
improving care while reducing costs. In an environment 
where change in care delivery models is being examined, 
pharmacists have an increased opportunity to play a role in 
improving public health. 
 
When providing MTM services, pharmacists often perform 
comprehensive therapy reviews of prescribed and self-care 
medications, resolve medication-related problems, optimize 
complex regimens, design adherence programs, and 
recommend cost-effective therapies.
6  MTM services 
encompass care beyond traditional medication counseling, 
and are  designed to maximize the benefits of prescribed 
medication regimens, increase medication adherence, and 
reduce the risk of adverse drug events and drug 
interactions.
6-8  Additionally, MTM services are designed to 
improve collaboration among pharmacists, physicians, and 
other health care professionals, enhance communication 
between patients and their health care team, and optimize 
medication use for improved patient outcomes.
10  Research 
has shown that pharmacist-provided MTM services have 
improved patients’ clinical, economic, and humanistic 
outcomes.
11-14 These services can occur in various locations, 
such as primary-care offices, outpatient clinics, patient 
homes, work-site health programs, senior centers, hospitals, 
and community pharmacies.
6   
 
In order for pharmacist-provided MTM services to operate 
effectively and efficiently, pharmacists must understand the 
process of MTM delivery, assess the barriers and challenges 
in creating a sustainable MTM program, and realize the 
willingness and readiness of their colleagues to deliver such 
services. Though MTM has been introduced in many states 
across the U.S., New York offers a unique environment that is 
not representative of other states (see Discussion). In order 
to assess feasibility of pharmacist-led MTM services among 
high-risk neighborhoods in New York City (NYC), a look at 
pharmacists’ perceptions of MTM is warranted, a topic that is 
explored by very few qualitative studies in the existing 
literature. We are only aware of one study done specifically in 
NYC where participants of a continuing education program 
were surveyed regarding their extent of MTM provision and 
attitudes, interest, and challenges related to delivering MTM 
services;
15 In order to appropriately assess feasibility of 
scaling up MTM in NYC, we felt further knowledge was 
needed through a method that would allow for detailed 
questions to gather more in-depth information. As such, we 
used a semi-structured focus group that allowed us to assess 
the immediate awareness and readiness of MTM among 
pharmacists. 
 
 
Background on our project 
As experience from other states demonstrates, 
implementing, scaling‐up and sustaining Medication Therapy 
Management (MTM) services to meaningfully impact public 
health will require supportive policies and alignment of 
stakeholder interests,  including effective communication 
linkages between primary providers and community 
pharmacists.
3,9  The current policy environment remains 
favorable with MTM being a key area of interest as the State 
of New York (NYS) works to redesign Medicaid to improve 
both efficiency and quality.
10 Preparedness, planning and 
stakeholder involvement are the vital next steps to enable 
effective MTM to succeed.
11‐13  
 
The Fund for Public Health in New York on behalf of the New 
York City Department of Health and Mental Hygiene (NYC 
DOHMH) received funding to develop a project that supports 
building the framework to introduce pharmacist-led 
Medication Therapy Management to high risk communities. 
 
Collaborating with a large network of primary care providers 
and pharmacists, this project aims to identify and convene 
champions and early adopters, and further engage them in 
assessing and improving readiness for MTM provision in NYC. 
To explore the feasibility of providing such services to NYC 
residents and to inform our work currently under 
development, the Bureau of Primary Care Information Project 
(PCIP) at the NYC DOHMH hosted focus groups. Researchers 
met with the Physician Advisory Board (PAB; comprised of 
champion physicians within NYC) and a group of community 
pharmacist leaders in the NYC area to learn about awareness 
of MTM and readiness to deliver these services to NYC 
residents. Findings from the PAB focus group are beyond the 
scope of this report. 
 
The findings from the focus groups provided key information 
to be considered in developing an MTM model in NYC and 
advised our efforts in working with NYS Managed Care 
organizations to create and implement an effective program 
to improve public health. 
 
Objective 
The goal of this exploratory study was to assess pharmacists’ 
perceptions of MTM services using qualitative methods. Our 
five objectives to address this goal were to assess: (1) The 
awareness of MTM services among champion community 
pharmacists in NYC; (2) Scope of current MTM services in 
NYC; (3) Willingness of pharmacists to deliver MTM services 
in NYC; (4) Readiness of community pharmacists to deliver 
MTM services to NYC residents; and (5) Pharmacists’ 
description of an ideal MTM model. 
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Methods 
Study Design 
A focus group design was used to qualitatively study the 
awareness and readiness of pharmacist-led medication 
therapy management (MTM) among pharmacists from the 
state of New York. Researchers from the NYC DOHMH 
conducted the focus group.  
 
Study Subjects 
Participants from this study included community pharmacists 
who are active members of the New York City Pharmacists 
Society (NYCPS), a member organization of independent 
pharmacists that accounts for about 40% of independent 
pharmacists within the NYC area. These pharmacists were 
selected based on their interest in MTM and are considered 
leaders in the pharmacy profession in New York. Pharmacists 
were recruited by invitation over email and responded based 
on their availability on the given focus group dates. 
Pharmacists who confirmed their attendance were then sent 
information on the purpose of the meeting. This included the 
APhA Promotional flyer for Pharmacists on MTM and a copy 
of the letter of support from the Surgeon General in response 
to Improving Patient and Health System Outcomes through 
advanced Pharmacy Practice. A Report to the U.S. Surgeon 
General, 2011.The pharmacists were instructed to read 
through these materials prior to attending the focus group 
which was held in a conference room at the New York City 
Department of Health and Mental Hygiene headquarters in 
Long Island City, New York.  
 
The study was approved by the New York City Department of 
Health and Mental Hygiene and the St. John’s University 
Institutional Review Boards. The two lead qualitative study 
investigators (V.A. moderator and T.K. note taker) are 
pharmacists. The interviews were conducted by one of the 
study investigators (V.A.) who has had prior experience 
facilitating focus groups. Using a model used by other studies, 
it was decided that a pharmacist investigator should conduct 
these interviews.
16A list of study questions and probing 
questions were identified prior to interviews. These questions 
were pre-tested with the members of the advisory panel, 
which was comprised of five individuals who were chosen 
based on their experience with MTM programs across the 
United States. Additionally, literature searches were 
conducted to assist in identifying key areas, including those 
that had not been previously studied. 
15-17, 19, 32 
 
Focus Group Script and Questions 
A detailed list of the questions used by the moderator can be 
found in Table 1. At the start of the session, after introducing 
herself and thanking the participants for their time, the 
moderator explained the purpose of the study   and informed 
participants that the research team would like to learn about 
their thoughts on challenges and barriers to implementing 
MTM services, pharmacist integration into primary care, and 
their previous experiences with MTM. Participants were 
made aware that the information collected would be used to 
aid our work on developing a model for MTM delivery among 
high-risk communities in NYC, advance public health 
knowledge, and improve the health of communities. They 
were then verbally asked for their consent to participate in 
the study.  
 
Upon receiving consent from all participants, the moderator 
described the structure of a focus group. This was done to set 
the tone for the session and to dispel any misconceptions. 
Participants were informed about the duration of the session 
and the presence of a note taker. They were informed that 
their  conversation  was  being  recorded  to  make  sure  the 
research team  would be able to capture exactly  what was 
said.  The  moderator  ensured  that  the  participants 
understood that the research team would not use their name 
for  any  of  the  information  that  would  be  used  from  their 
conversation.  
 
In order to create a comfortable environment for the group, 
participants  were  informed  that  they  could  withhold  from 
answering any questions as they saw fit, and could leave the 
group at any point during the conversation. Participants were 
encouraged  to  talk  with  each  other  and  not  just  the 
moderator,  and  to  verbally  acknowledge  if  they  agreed  or 
disagreed with any points made by fellow participants. They 
were told that there were no correct or wrong answers and 
were  reminded  to  let  each  person  complete  his  or  her 
thoughts before speaking so as to offer each participant an 
equal opportunity to voice their opinions.  
 
Before the session began, the participants were asked to 
introduce themselves using their first name, their pharmacy 
practice site and location in NYC, and how many years they 
had been in practice (Demographic information is provided in 
Table 2). Participants’ responses were both noted and audio 
recorded. Researchers later assessed the notes, listened to 
the recorded conversations, and transcribed the participants’ 
responses. Transcripts were read and themes from the 
conversations were chosen and summarized in the results 
section to follow.  
 
Results 
There were 10 community pharmacists/owners at the focus 
group session. Table 2 presents the demographic 
characteristics of the participants.  
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NYC Community Pharmacists’ awareness of MTM services 
Participants were asked what the term MTM meant to them. 
All participants were familiar with the term, and some were 
familiar with pilot studies involving pharmacist-led MTM, 
particularly a former pilot done in New York State. Although 
all participants were familiar with the term MTM, 
pharmacists were unclear on the formal structure and 
process of MTM in relation to daily activities formed by the 
pharmacist.  
 
Assessment of current MTM services in NYC 
It was hypothesized that pharmacists with previous MTM 
experiences would have different perceptions when 
compared with those who had not had previously delivered 
MTM services. The group was asked details about MTM 
programs they may have participated in, challenges they have 
faced, barriers to providing MTM for those who did not have 
experience delivering MTM services (referred to hereafter as 
“non-deliverers”), and resources that would be needed to 
conduct MTM. It was noted that at least three pharmacists 
had participated in providing MTM services in the past. The 
remaining participants were not presently delivering MTM. 
The participants that had provided some MTM used existing 
documentation platforms, such as OutcomesMTM™, Mirixaﾮ, 
and PharmMD, to document interventions, and at least one 
participant operated an MTM call center using Mirixa® as the 
documentation platform.  
 
As a collective group, challenges mentioned included: 
reimbursement; lack of interest by patients; timely 
communication with physicians; resources required; 
integration of MTM into regular workflow; and costs. 
Participants felt they would like to do more, but must have 
adequate resources and make MTM quantifiable with clear 
expectations and objectives. Participants believed they need 
to have resources and clear objectives within their program in 
order to make their MTM services financially sustainable and 
receive the best patient outcomes possible. The non-
deliverers discussed barriers such as costs, lack of timely 
communication with providers, lack of collaborative drug 
therapy management legislation outside of teaching hospitals 
in New York State, and the inability to retrieve labs and 
patient-specific data.  
 
Even though a high percentage of participants were not 
actively delivering MTM, 8 of 10 said they currently have 
designated private space to provide MTM services and would 
have supporting staff as long as they were paid for it. 
Participants felt uneasy and unsure about hiring more 
employees solely to provide MTM. They were concerned 
about separating pharmacists’ time and duties between 
conducting MTM and filling prescriptions. Participants 
thought that having one pharmacist solely dedicated to MTM 
and another pharmacist solely dedicated to dispensing 
prescriptions would cause some disconnect or lack of 
communication. One participant said, “If I separate the job, if 
you’re doing the MTM and another person is doing the filling 
then you’re not going to be real effective at doing the 
filling….you’re probably better doing both parts of the job 
because there’s going to be disconnect.” (Pharmacist 5). 
Another concern placed emphasis on having sufficient patient 
clientele before MTM would be feasible. One of the 
pharmacy owners specifically expressed, “If you don’t have 
the patients you’re not going to have MTM…so as owners 
[we] still need to think about filling prescriptions to bring 
patients in the door.” (Pharmacist 5).  
 
 Reimbursement was identified as an important issue with 
both deliverers and non-deliverers of MTM. This issue was 
raised earlier with deliverers and was discussed again with 
non-deliverers. Participants were concerned that if a 
pharmacist split his/her time between dispensing and MTM 
services, reimbursement would be a problem. Their primary 
concern was that the current reimbursements system is 
product-specific rather than service-specific. One participant 
declared, “Well [even as of now], we only get reimbursed on a 
product, on a drug; so, pretty much, we’re not pharmacists, 
we’re people who put pills in a bottle.” (Pharmacist 5). 
Another said, “Right…it becomes all about volume…the more 
prescriptions you fill; it’s the only way to make it.” 
(Pharmacist 4).  
 
Although a number of resource issues and barriers were 
presented, participants were in favor of being paid for their 
expertise/service. A strong underlying sentiment was that 
providing MTM services could potentially transform practice 
models and sustain their business, specifically in light of 
emerging mail-order services, and preserve existing 
relationships so patients continue to consult their pharmacist 
of choice. One pharmacist stated, “The value of having a 
consultation with your local community pharmacist, rather 
than what’s happening with so many plans right now, they’re 
trying to steal business away and ship it out-of-state….I don’t 
care what anybody says, a consultation over the phone with a 
pharmacist somewhere in another state [who] doesn’t know 
you…it’s not going to work.” (Pharmacist 6). Another 
participant agreed by saying, “It [phone consultations with 
pharmacist other than the pharmacist of choice] doesn’t 
work…it doesn’t work….it doesn’t work.” (Pharmacist 7). 
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Willingness of NYC community pharmacists to deliver MTM 
services 
The group discussion revealed that the participants were 
willing to deliver MTM services as long as the following key 
elements were in place:  
 
1.  Familiarity with structure of MTM. Participating 
pharmacists thought as long as their MTM program 
had some type of structure, they would be willing to 
deliver MTM services. One pharmacist said, “If it’s 
properly structured, I think 90% of pharmacists 
would do it.” (Pharmacist 1). Another stated, “I think 
that number is high but reachable…depends on 
reimbursement.” (Pharmacist 2).  
2.  Opportunities for reimbursement for services 
provided. Based on the group’s discussion, 
opportunities for reimbursement were mentioned as 
an important element of their willingness to deliver 
services. One participant declared, “MTM has to be 
properly structured, [with] no interference from 
PBMs, and something pharmacists can afford to 
provide based on some kind of reimbursement.” 
(Pharmacist 1).  
3.  Ability to foster collaborative efforts with providers. 
Participants believed the ability to communicate 
timely with physicians about medications and 
patients, and forming relationships for collaborative 
drug therapy management was necessary for 
delivery of MTM. 
4.  Training and access to documentation systems and 
patient information software. Participants expressed 
the importance of understanding how to use, and 
have access to, software systems and all drug 
information for patients. One pharmacist stated, 
“Very definitely we have to have access to all of the 
drug information.” (Pharmacist 2).  
5.  Income generated by services for program 
expansion. Participants expressed the need to have 
steady income to compensate for the time needed 
to provide MTM services, before it would be feasible 
to scale up to a sustainable program. One of the 
participant stated, “It will take time because we need 
to see money coming in before restructuring stores, 
making space, and hiring people.” (Pharmacist 3).  
 
One pharmacist was concerned that offering MTM services 
would add more responsibility and liability while others did 
not express the same concern. The concerned participant 
stated, “I think other pharmacists’ concern about doing MTM 
will be there if more responsibility and liability… is 
considered.” (Pharmacist 4). Others disagreed and their 
thoughts were summarized by Pharmacist 2, “I disagree. 
There’s no more liability [with MTM services] than handing 
somebody aspirin and Coumadin in the same bottle and not 
saying anything…liability will be there just in a different 
context.” Participants felt that independent community 
pharmacists provided a better level of patient care and 
involvement when compared to chain pharmacies, and thus 
would have an advantage over chain pharmacies in offering 
MTM services. Pharmacist 1 added, “I personally think 
eventually it will be 100%... that with time, competition, and 
the services being provided, all those who are not doing MTM 
will be forced to do it or be out-of-business.”  Three other 
participants agreed with this comment.  
Participants were also asked where they would like to deliver 
MTM services, and how they preferred to document these 
interactions with patients. Two participants felt MTM should 
be delivered at the pharmacy itself, while another offered 
that a mixed model may be better, based on patient 
preference. Pharmacist 1 declared, “I think it should be part 
of your pharmacy, not away from it.”  Another participant 
stated, “I’d say whatever works best for the patient. You may 
be dealing with some clients who may not, cannot, or will not, 
come to the pharmacy for a number of reasons.” (Pharmacist 
5).   
 
Participant responses to preferences on documentation 
methods included various components that were deemed 
critical: 
 
1.  Read and Write Ability: Having an electronic system 
that allows  pharmacists to access and update 
information;  
2.  Access to Patient Data: A system that provides 
access to pertinent patient data, including medical 
records, lab results, and medication lists, such as 
history and current use of prescriptions, over-the-
counter medications, supplements and 
recreational/street drugs, if any; and  
3.  Interoperability: A system that is interoperable with 
the electronic health records used by physicians. 
 
Readiness of NYC community pharmacists to deliver MTM 
services 
The statement, “The majority of pharmacists are not ready to 
do MTM on a large scale,” (Pharmacist 3) adequately 
represents the sentiments felt and expressed by the group. 
All participants agreed that additional training is required. 
Topics for training included the structure and process of 
MTM, clinical treatment guidelines or algorithms for major 
chronic disease states, and documentation. Participants felt 
training should be ongoing and consistent rather than a one-
time offering. As it relates to protocols/algorithms, one 
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recently passed NY pharmacist collaborative practice 
legislation in 2011, “Someone has to stop the noise and say 
okay, it may not be perfect, but we’re going to agree that this 
is what we are going to do with these patients…get the 
patients to cooperate, see how it works, and just find a place 
where we can start from…draw some parameters and come 
up with an algorithm.” (Pharmacist 5).  
 
Participants felt they needed more familiarity with existing 
documentation systems to help with choosing 
software/platforms to help document pharmacist services. 
Participants also felt that having experience offering clinical 
services in the past often builds confidence and helps 
pharmacists in either expanding current services, or offering 
new services. The moderator therefore asked participants 
about the software they use at their pharmacies, and 
whether they offer immunizations at their pharmacies. 
Different types of pharmacy software were mentioned, 
including OPUS ISM, QS/1, Micro Merchant Systems, Best 
Computer Systems, and Visual Superscript. Three of the eight 
participants who spoke said they were certified immunizers in 
New York State. One of the three has been consistent in 
providing immunizations, while another participant only 
recently began immunizing at their pharmacy. The third 
individual declared to be a certified immunizer, but currently 
chooses not to provide this service. 
 
Pharmacists’ description of an ideal MTM model 
Participants were asked how their ideal MTM model would 
operate. Though none of the participants provided exact 
details of their ideal MTM model, they described elements of 
what they felt was critical for an ideal program. One 
important element that was commonly expressed among the 
participants was having access to patients’ medical 
information. One participant stated, “[I] would like to have 
more information than just knowing what drugs the patient 
was taking.” (Pharmacist 4). Another common element 
expressed was ability to communicate with other health care 
providers in a timely manner. Pharmacist 8 stated, “I want a 
situation where I can directly reach my patients and the 
physicians with no interactions from PBMs or insurance 
companies from hindering me.” Another participant agreed 
by expressing the “need to have easy access to the doctor to 
make a recommendation [so that the doctor is] able to get 
back to you right away.” (Pharmacist 4). Pharmacists seemed 
to support the face-to-face one-on-one consultation model. 
One participant stressed the importance of allocating 
dedicated time for the consultation. “The ideal situation is the 
patient comes in and you take the time not just for a quick 
consultation or history, but at least 10-20 minutes to talk with 
the patient.” (Pharmacist 6).  
 
A final element that was common amongst the participants 
was the concept of having adequate reimbursement for 
providing MTM services; at least six participants were vocal in 
specifically expressing reimbursement as a key element for 
providing MTM services. As discussed previously, participants 
continued to express that reimbursement was needed to 
obtain resources and equipment for staff. Equipment was 
stated to include, but not be limited to, an internet-based 
platform to access patient information, including medication 
history and any pertinent data, where such information could 
be accessed, entered, and transmitted easily.  
In discussing an appropriate reimbursement model, 
participants had several different suggestions. According to 
pharmacist 4, “Ideal MTM would be differential 
reimbursement based on pharmacists’ acceptable levels, not 
imposed by somebody else, but acceptable to us.”  Some 
expressed that reimbursement should be scalable to 
incorporate the various levels of interventions. “Pharmacists 
should receive a certain fee for contacting a patient, certain 
fee for talking with a patient, a certain fee for making 
therapeutic changes, different levels of intervention, etc.” 
(Pharmacist 2). According to pharmacist 5, “it should not be 
unlike what a provider gets for an initial visit, a 
consultation...like the… codes they use for different levels of 
intervention.” Another participant stated, “acceptable level 
would be based on current costs of the pharmacist…I think 
$2.50 a minute is fair.” (Pharmacist 1). Six out of the eight 
vocal participants were in favor of a tiered system with 
specific fees for different components of MTM; one 
participant disagreed, and another participant was neutral on 
the topic. Six participants were neutral to the idea of a time-
based model of reimbursement. Every participant preferred 
the complexity-based model that would pay for pharmacist 
service based on complexity of the patient, similar to the 
model used by the American Medical Association
18; however, 
participants also expressed the need for flexibility to adjust 
the model as needed based upon its success or lack thereof. 
One participant said, “Whatever I would pick, I would like to 
have the opportunity to change in the future depending upon 
what’s working or not working at the time.” (Pharmacist 1).  
 
At the end of the focus group session, participants were 
asked if they had any final questions. Patient engagement 
and sustainability were the main topics that were brought up 
by participants to ensure success with any MTM service. 
When asked about interest in participating in a small pilot 
study in the future, all ten participants stated strong interest 
to do so.  
Table 3 summarizes the results from the thematic analysis.     
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Discussion 
Overall, participants felt that pharmacists are generally aware 
of the term MTM. Participants in our focus group were still 
unclear about the formal structure of MTM compared to daily 
pharmacist activities. Lack of  training, knowledge, and skills 
specific to MTM delivery have been previously cited as 
barriers for providing MTM services, and this was also 
confirmed through our focus group.
19 Research has shown 
that the pharmacy profession, through its many professional 
associations and organizations, has been active in the 
development of MTM models
20, consensus definitions
21, and 
core element/structural framework.
10,21 Although the 
professional associations and organizations have invested a 
lot of time and effort in coordinating MTM educational 
opportunities for pharmacists, there is still a need for 
additional, continued education on the topic, particularly 
regarding consistency and standardization of MTM delivery. 
Interactive methods have been shown to be more effective 
than didactic when it comes to educating health care 
professionals.
22-23 Examples of interactive methods including 
video-clip observations, videotaped vignettes, role plays or 
simulated teaching activities, and discussion groups following 
workshops.
22,24-26  Other types of educational methods 
include lecture-based teaching (i.e. meetings, conferences, 
continuing education programs, and on-line resource 
modules), on-line readings, mailed materials, websites, 
publications, etc.
23,26-28  These responses from community 
pharmacists compared to MTM studies in other parts of the 
U.S. confirm that regional variations in MTM provision and 
training do exist.  
 
As far as the need for additional training goes, literature 
supports this finding that additional training may be needed 
for conducting MTM services.
19 Current certification 
programs and MTM training sessions are geared toward the 
theoretical understanding of the term MTM but offer little 
assistance when it comes to explaining the ‘How-tos.’ The 
pharmacists in this study felt that they needed to have a 
better understanding on the structure and process 
surrounding MTM. Professional organizations and universities 
should focus on helping current and future pharmacists 
understand the practical aspects of MTM by training them on 
the structure and process associated with MTM delivery. . 
Professional organizations could help their members by 
offering such sessions during annual meetings.  
 
In general, pharmacists have felt most comfortable with the 
services they perceived as highly valued by patients, and least 
comfortable with those services perceived as having lesser 
value, such as development of a medication action plan or 
educating about disease prevention services. Higher-level 
skills are generally required to perform the least comfortable 
services, which is probably due to the pharmacists’ relative 
unfamiliarity with those types of services.
18 By having access 
to additional training opportunities and refresher courses, 
pharmacists may be better equipped to provide 
comprehensive MTM-related services. Additionally, it was 
noticed in the focus group that five of the eight participants 
that spoke were in practice for eighteen years or more. This 
would lead us to believe that the majority were older 
generation pharmacists who may or may not have received 
extensive education and training in patient-centered care and 
MTM during their years in pharmacy school.  As more 
clinically trained pharmacists start entering the work force 
and gain more work experience, we may see a change in the 
provision dynamic, particularly as new curricula have 
increasingly emphasized the concept of patient-centered 
care.  
 
Another perception that is valuable to understand is how 
pharmacists feel about the challenges/barriers of providing 
MTM services. Once pharmacists are aware or have a better 
understanding about the structure, the next step would be 
designing and implementing or providing the service. 
Reimbursement, having appropriate resources, 
communication between physicians and pharmacists, patient 
interests, and costs were all concerns from MTM deliverers 
and non-deliverers. These challenges are commonly cited in 
the literature when it comes to providing MTM and cognitive 
services.
20, 29-32  
 
Reimbursement has been a contentious issue for many years, 
and much of the discussion from our focus group was 
centered on this issue. Ideas for reimbursement included: 
receiving varied fees based on different levels of service 
similar to what physicians currently use;  reimbursement 
based on current costs of a pharmacist (a set fee per minute 
of MTM); and a tiered system with specific fees for different 
components of MTM. Opinions regarding time-based models 
versus complexity-based models were varied among the 
participants. The majority of the participants felt having a 
tiered, complexity-based model for reimbursement would be 
best. . Many institutions have provided ambulatory care 
pharmacy services in combination with cognitive services for 
years, with or without viable methods for reimbursement. 
Pharmacists who offer cognitive services within ambulatory 
care settings have long justified being reimbursed for clinical 
services based on improved clinical outcomes, patient and 
provider satisfaction, and indirect revenue through cost-
avoidance strategies.
32 Historically, pharmacists have pursued 
reimbursement for clinical services through first-party 
payment (direct payment by patient), incident-to billing, and 
the use of facility fees.
32 It is only recently that pharmacists 
have been recognized in the form of current procedural Original Research  PHARMACY PRACTICE 
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terminology (CPT) codes and have been able to submit claims 
for providing MTM services.
33,34 Various reimbursement 
models and billing practices have recently been assessed.
35-38 
Literature supports the pharmacists’ concern that figuring out 
feasible ways to reimburse for the provision of MTM services 
is necessary and important for the profession.
39 Research is 
needed in this area on feasible business models and 
reimbursement strategies for pharmacist-provided MTM 
services. Similar to other studies, concerns about 
reimbursement persist, including concerns that 
reimbursement levels will not cover the costs of provision of 
MTM services.
33,39 Through additional research, newer, 
innovative strategies for improving the reimbursement 
system for MTM services can be created, implemented, and 
evaluated.   
 
A contrast between MTM deliverers and non-deliverers was 
noted on the issue of resources. MTM non-deliverers were 
not comfortable with hiring employees solely dedicated to 
MTM. Allocation of resources, such as pharmacy staff, space, 
and time, has been a challenge and barrier to providing MTM 
services.
19 These findings from our focus group are 
understandable because pharmacists who have not delivered 
MTM services have not experienced the benefit from MTM 
and may therefore struggle with the idea of investing 
resources. On the other hand, one of the MTM providers 
made the following statement: “…when we started our MTM 
program we were using our own people to do the MTM stuff. 
Once you start getting paid and the program expanded we 
couldn’t do it anymore…we brought people on, some were 
part-time, some worked for three months, one month, etc…”  
This shows that as pharmacists deliver MTM services and 
programs grow, additional resources are needed to handle 
the responsibilities. As was described by one of the 
participants, however, once reimbursement is acquired for 
these services, pharmacies can start using that money toward 
additional resources, thereby eradicating some of their 
resource barriers.  
 
Participants expressed that they, as well ask their colleagues, 
would be willing to deliver MTM services given some key 
components such as knowledge about the MTM program 
structure, reimbursement, and fostering collaborative efforts 
between physicians and pharmacists. Structure and 
reimbursement have already been discussed earlier in this 
paper. Another willingness element that participants 
mentioned was fostering collaborative efforts between 
physicians and pharmacists. Collaboration among health care 
providers is important when providing the highest quality of 
care for patients,
40-44  and has drawn much attention among 
providers in an effort to improve patient safety and achieve 
better therapeutic outcomes.
46 There is increasing 
recognition of the value of having shared responsibility 
among primary care providers and pharmacists to ensure 
appropriate, safe, and cost-effective medication use.
6 In 
regards to documentation efforts, research has shown that 
continuous efforts are being made by focusing on 
documentation systems and the use of health information 
technology in the provision of MTM services.
47,48 With 
progress towards a team-based system of care and more 
advanced technologies, it may not be long before this barrier 
is broken.  
 
Regarding readiness to deliver MTM services, participants 
from our focus group did not think they or their colleagues 
were ready to implement MTM services on a large scale. 
There was unanimous agreement that more training was 
important and required for pharmacists to deliver MTM 
effectively. Training topics included structure/process of 
MTM, structuring guidelines or algorithms for patients with 
various disease states, and training on documentation 
methods. It was noted during the session that very few of the 
pharmacists offered immunizations at their pharmacies. 
Possible reasons may be lack of enough time or appropriate 
staff to handle additional clinical responsibilities; lack of 
confidence in their training, knowledge, or skills; or feeling 
unprepared to provide clinical services including 
immunizations due to lack of training . It has been discussed 
in previous studies that legal liability is also a concern and 
barrier to the provision of immunization services.
29 Since 
liability has been a concern with other services, it would 
make logical sense, that some pharmacists would have a 
similar concern with MTM. At least one pharmacist in the 
group felt that liability could be an issue with delivering MTM 
services.   
 
Although preferred setting for MTM delivery varied from 
community pharmacy to a more mixed setting approach, 
most pharmacists preferred the community pharmacy as the 
main site for MTM practice. When discussing documentation 
methods, the consensus was to have an electronic system 
where medical and pharmacy information was integrated so 
all health care providers could access the same, all-inclusive 
patient health information 
 
Overall, pharmacists’ description of their ideal MTM models 
focused around four key areas:  access to medical 
information for their patients, efficient communications with 
health care providers, time with patients, and reimbursement 
for services.  
 
Conclusion 
The results of our study favor the need for education and 
structure around a standard and consistent way of delivering Original Research  PHARMACY PRACTICE 
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MTM services. Reimbursement and allocation of resources 
were the most discussed challenges/barriers to the provision 
of pharmacist-provided MTM services. Pharmacists stated 
they were willing, but not ready to provide MTM services on 
a large scale. Lack of understanding of the structure, 
reimbursement challenges, and the need for collaboration 
between providers were key components to pharmacists’ 
willingness to provide services. Additional training 
opportunities were deemed necessary for them to feel 
confident to conduct clinical services. Although pharmacists 
discussed several issues regarding MTM, they were still 
interested in participating and seeing how MTM would 
impact their community practice settings. Understanding 
these perceptions of pharmacists on MTM allowed us to 
better understand and assess ways for continuous quality 
improvement of services that will enhance patient care. 
 
Public Health Impact  
As health care continues to evolve, MTM looks to be at the 
forefront of how pharmacists can be a central piece of the 
health care puzzle and play a major role on improving the 
lives of millions of patients. With continued focus on pay-for-
performance and quality improvement, emerging care 
delivery systems can benefit from pharmacist interventions. 
The recent report to the Surgeon General, outlines the 
evidence base demonstrating positive impact of pharmacist-
delivered care in health care system.
49 Looking towards the 
future of public health, with strong emphasis towards 
reducing the burden of chronic disease, pharmacists’ 
interventions can greatly contribute to reducing health care 
costs and improving the quality of care every patient 
deserves. 
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Table 1: Focus Group Question Guide for MTM Awareness among pharmacists in NYC 
 
Awareness of NYC Community Pharmacists about MTM services: 
1.  How familiar were you with Pharmacist-led Medication Therapy Management (MTM) prior to receiving 
the materials that were sent to you?* 
 
Assessing current MTM services in NYC: 
2.  Can you describe what types of MTM services patients are receiving, by whom and where are these 
services being provided? 
3.  What are some of the challenges you face in providing these services? Would you like to be able to do 
more? 
4.  For those of you not delivering MTM Services, what has kept you from providing these services? 
 
Willingness of pharmacists to deliver MTM services in NYC: 
5.  How willing do you think community pharmacists in New York City will be to deliver MTM services as part 
of their pharmacy operations? 
6.  What is the preferred setting where you would like to offer MTM (e.g. clinic or a doctor’s office vs. 
pharmacy)? How would you provide these services – exclusively at one place or a combination? 
7.  How would you like to actually document, or record, your interaction with the patient? 
 
Readiness of NYC community pharmacists to deliver MTM services to NYC residents: 
8.  How ready do you feel as a pharmacist or in general pharmacists are to provide MTM? Do you think more 
training or information is needed? 
9.  What kind of training do you think pharmacists can get that would level the playing field whether it be 
process, disease state, documentation? 
10.  Do you think there needs to be some kind of ongoing component to the training? 
11.  What kind of documentation software does your pharmacy use? 
12.  Do you offer immunizations at your current pharmacies?  
 
Pharmacists’ description of ideal MTM model: 
13.  In an ideal scenario, not looking at anything existing, what would you want MTM to look like? 
14.  What would you, and do you think other pharmacists, would favor in terms of two models, one being time 
based and the other one based on complexity of care? 
 
Wrap-Up: 
15.  Would you or any pharmacists you know be interested in participating in our pilot to run a process 
evaluation? 
 
*Refers to the American Pharmacists Association Promotional Flyer for Pharmacists and a letter of support from the 
Surgeon General in response to “Improving Patient and Health System Outcomes through advanced Pharmacy Practice. A 
Report to the U.S. Surgeon General, 2011.” Original Research  PHARMACY PRACTICE 
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Table 2. Demographic characteristics of NYC community pharmacists participating in a focus group  
to assess awareness and readiness for Medication Therapy Management (N=10) 
 
Characteristic  Number (%) 
Gender   
     Male  9 (90) 
     Female  1 (10) 
   
Practice location (NYC borough)   
     Queens  7 (70) 
     Bronx  1 (10) 
     Manhattan  1 (10) 
     Manhattan & Queens  1 (10) 
        
Years of experience   
     0-10      3 (30) 
     11-20  4 (40) 
     21-30  2 (20) 
     >30  1 (10) 
Approximate mean for years of experience was 20.5 (SD 8.9)   
All participants hold a B.S. degree in pharmacy   
Abbreviation used: NYC, New York City 
Eight of the ten participating pharmacists were highly vocal and participated throughout the one hour discussion period.  Original Research  PHARMACY PRACTICE 
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Table 3: Awareness of and Readiness for Medication Therapy Management among Community Pharmacists 
 in New York City: Summary of Focus Group Findings 
 
Awareness of NYC Community Pharmacists about MTM* services: 
  All participants were familiar with the term 
  For some participants, familiarity extended to pilots studies, especially those conducted in the state of 
New York 
  Pharmacists were unclear on the formal structure and process of MTM in relation to daily pharmacist 
activities 
Assessing current MTM services in NYC: 
  It was noted that at least 3 pharmacists had participated in providing MTM services in the past using 
documentation platforms such as Outcomes and Mirixa 
  MTM Deliverers: Challenges include reimbursement, lack of interest by patients, timely communication 
with physicians, resource issues, and costs.   
  MTM Non-Deliverers: Barriers include costs, timely communication with providers, lack of fostering 
collaborative drug therapy management relationships, and ability to retrieve labs/data 
Willingness of NYC community pharmacists to deliver MTM services: 
  Pharmacists would be more willing to deliver MTM provided the following key elements were met. 
  Familiarity with structure of MTM  
  Opportunities for reimbursement 
  Ease and ability to foster collaborative efforts with providers 
  Training and access to documentation systems/software 
  Income generated from current small scale services could assist in program expansion 
Readiness of NYC community pharmacists to deliver MTM services: 
  They were ready to deliver MTM but not on a large scale 
  Biggest drawback was the need for additional training in various areas:  structure, clinical treatment 
guidelines or algorithms for different disease states, and documentation. 
Pharmacists’ description of ideal MTM model: 
  Pharmacists description of an ideal MTM model Focused around four key areas:   
  Access to patients’ medical information 
  Ability to communicate with health care providers in a timely manner 
  Having time with patients 
  Receiving adequate reimbursement for services 
Wrap-Up: 
  All participants were very interested in participating in future MTM programs 
*Abbreviation used: MTM, medication therapy management 
 